~~<i id='3227FC87C6'><strike id='3227FC87C6'><tt id='3227FC87C6'><pre id='3227FC87C6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：knowledge 2025-08-20 09:42:16 - browse：113

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Wikipedia

explore

leisure time

explore

Wikipedia

Illustration:ChristineKao/STAT;Photos:AlissaAmbrose/STAT,Adobe,MichaelStarghillforSTATFederalofficia

WSS

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Cassava reveals details — and problems — with Alzheimer's study

Cheap, fast test for Zika and dengue could cost just $1

My daughter's legacy lives on through her writing, phage therapy

Cheap, fast test for Zika and dengue could cost just $1

California wildfire smoke linked to 52,000 early deaths, study says

hotspot

fashion

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Curing rare childhood diseases will falter unless Congress steps up

Walensky prepares to leave CDC — and Congress — behind

WHO may add ‘noma' to its list of neglected tropical diseases

Virginia high school admissions case could be legal follow

Hospitals warn Medicare's drug payment fix is ‘unlawful’

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Senate panel to vote on hospitals, PBMs, prisoner care

Activists slam private health insurers over coverage restrictions

Readers discuss the intersection of pregnancy and addiction

explore

STAT Virtual Event: ASCO Recap, Live!

Testing for cancer recurrence creates a new limbo for patients

NIH tests clinical research in primary care with $30 million program

Why Sanofi got shellacked over its spinoff

Why Sanofi got shellacked over its spinoff

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

leisure time

explore

Wikipedia

Wikipedia